bioMérieux 2022 Financial Results
bioMérieux announced a strong performance in 2022 with robust full-year sales at €3,589 million with a reported growth of +6.3% and an almost neutral organic growth of +0.2%.
bioMérieux announced a strong performance in 2022 with robust full-year sales at €3,589 million with a reported growth of +6.3% and an almost neutral organic growth of +0.2%.
Swipe to discover more
BioFire Defense, LLC, has received a contract from the BARDA (Biomedical Advanced Research and Development Authority) to accelerate development of the Specific Diagnostics SPECIFIC REVEAL™ Rapid AST System that can deliver phenotypic results in an average of five and a half hours from positive blood cultures.
Patients who are admitted to the hospital with large burn injuries are at especially high risk for developing hospital-associated infections (HAIs), and the longer a patient stays in the hospital, the more likely they are to acquire a resistant infection.
At bioMérieux, we support the inclusion, well-being and development of our team members and are committed to creating a culture of belonging and acceptance where all feel respected, supported and included.